ArticleCancer2025
The association between human papillomavirus type 16 seropositivity and oropharyngeal cancer among men living with HIV.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThere are no methods for the early detection of human papillomavirus-driven oropharyngeal squamous cell carcinoma (HPV+OPSCC); however, HPV16 E6 seropositivity has been identified as a promising screening marker. Although people living with HIV have a higher risk of developing HPV+OPSCC, few studies have evaluated the association between HPV16 antibodies and HPV+OPSCC.
methodsThe association between HPV16 seropositivity (L1, E1, E2, E4, E6, and E7) and OPSCC was assessed among 2331 men living with HIV (MLWH) aged ≥40 years who had blood specimens banked within the Tennessee Center for AIDS Research biorepository between 2001 and 2019; some samples were collected before OPSCC diagnosis, and others after. The association between HPV16 seropositivity and OPSCC was analyzed via univariable logistic regression.
resultsOne hundred and thirty-five HPV16 E6 seropositive cases and 11 OPSCC cases were identified. HPV16 E6 seropositivity was associated with a 14-fold higher odds of OPSCC (odds ratio [OR], 14.04; 95% CI, 4.23-46.61; p < .001); five of the 11 OPSCC cases were HPV16 E6 seropositive (sensitivity, 45%; 95% CI, 17%-77%) compared to 6% of controls (specificity, 94%; 95% CI, 93%-95%). Seroreactivity against HPV16 E1 (OR, 7.14; 95% CI, 1.52-33.67; p = .013), HPV16 E2 (OR, 16.43; 95% CI, 4.94-54.65; p < .001), and HPV16 E7 (OR, 13.84; 95% CI, 3.99-48.11; p < .001) was also significantly associated with OPSCC. HPV16 E6 antibodies were detectable up to 9 years before and 19 years after OPSCC diagnosis.
conclusionsAmong MLWH, HPV16 E6 antibodies are strongly associated with OPSCC, yet point estimates of the sensitivity and specificity of HPV16 E6 antibodies for OPSCC were lower compared to studies in populations without HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.